Témata
- Surgery and staging
- Radiation oncology
- Adjuvant therapy
- Special topics in thoracic oncology
- Advanced NCSLC
- Targeted therapies and immunomodulation
- Biomarkers
Registrace
- Zlevněná registrace do 22. září 2011
- Online registrace
- 2. oznámení (PDF)
Program
Session I: Introductory lectures
8:00 am Welcome
8:10 am Lung cancer screening in 2011: Current reality and results from recent clinical trials
8:30 am Therapeutic economics and implications
8:50 am Pathology: What is the most effective and practical way of assessing molecular markers?
9:10 am Panel discussion and knowledge/confidence assessment of the audience via ARS survey
9:30 am Break
Session II: Surgery and staging
9:50 am Pre-activity knowledge/confidence assessment of the audience via ARS survey
9:55 am The intricacies of staging in NSCLC
10:15 am Debate: Surgery versus radiation therapy in patients with operable early stage NSCLC
10:45 am Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey
11:05 am Lunch
Session III: Radiation oncology for the uninitiated and perpetually perplexed
12:40 pm Pre-activity knowledge/confidence assessment of the audience via ARS survey
12:45 pm State of the art combined modality therapy
1:05 pm Integrating modern imaging and technology with therapy in LA-NSCLC
1:25 pm Novel approaches to radiation therapy in the palliative settings
1:45 pm Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey
Session IV: Prevention and early stage NSCLC
2:05 pm Pre-activity knowledge/confidence assessment of the audience via ARS survey
2:10 pm Rethinking strategies for chemoprevention in lung cancer
2:30 pm Ongoing clinical trials in the adjuvant arena
2:50 pm Adjuvant therapy: State of the art in 2011
3:10 pm Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey
3:30 pm Break
Session V: Special topics in thoracic oncology
3:50 pm Esophageal cancer: Therapeutic updates
4:10 pm New insights in the management of mesothelioma
4:30 pm SCLC: An orphan disease. Who will adopt?
4:50 pm Updates on thymoma
5:10 pm Panel discussion and knowledge/confidence assessment of the audience via ARS survey
5:30 pm Closing notes and adjourn
Session VI: Advanced NSCLC
8:00 am Welcome to day two
8:05 am Pre-activity knowledge/confidence assessment of the audience via ARS survey
8:10 am Using histology to personalize therapy
8:30 am Role of EGFR TKIs as front line therapy in mutation positive patients with NCSLC
8:50 am Is ERCC1 and RRM1 ready for prime time?
9:10 am Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey
9:30 am Break
9:50 am Pre-activity knowledge/confidence assessment of the audience via ARS survey
9:55 am Debate: What is the optimal extended therapy approach?
10:40 am Therapeutic options in the salvage setting
11:00 am What options exist for patients with compromised performance status
11:20 am Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey
11:40 am Lunch
Session VII: Supportive therapy
12:40 pm Practical tips on the management of toxicities with EGFR and VEGFR inhibitors
1:00 pm Preventing myelosuppression in treatment of advanced disease
1:20 pm Management of bone metastases in NSCLC
1:40 pm Panel discussion and knowledge/confidence assessment of the audience via ARS survey
Session VIII: Biomarkers
2:00 pm Pre-activity knowledge/confidence assessment of the audience via ARS survey
2:05 pm EML4/ALK and other new biomarkers and their therapeutic implications
2:25 pm The expanding role of proteomics
2:45 pm Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey
3:05 pm Break
Session IX: Targeted therapies
3:25 pm Pre-activity knowledge/confidence assessment of the audience via ARS survey
3:30 pm Angiogenesis inhibition: Bevacizumab and beyond
3:50 pm MET kinase inhibitors as therapeutic agents
4:10 pm New targeted agents on the horizon
4:30 pm Immunotherapy: Has its time arrived?
4:50 pm Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey
5:10 pm Closing notes
5:15 pm Adjourn
Kontakt: meetings@imedex.com
Web: http://imedexinc.c...mp;scriptid=index1
- Přidat do kalendáře: 2011-11-18 00:00:00 2011-11-19 23:59:59 Europe/Prague 16th Annual Perspectives in Thoracic Oncology Témata Surgery and staging Radiation oncology Adjuvant therapy Special topics in thoracic oncology Advanced NCSLC Targeted therapies and immunomodulation Biomarkers New York, USA